BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 30639823)

  • 21. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
    Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
    Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
    Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
    Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
    Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009.
    Rosengren S; Mellqvist UH; Nahi H; Forsberg K; Lenhoff S; Strömberg O; Ahlberg L; Linder O; Carlson K
    Bone Marrow Transplant; 2016 Dec; 51(12):1569-1572. PubMed ID: 27694943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
    Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
    Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
    Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
    Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Novel Agents and Stem Cell Transplantation to Optimally Manage Immunoglobulin Light Chain Amyloidosis.
    Gertz MA
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1339-40. PubMed ID: 25899453
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
    Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
    Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
    [No Abstract]   [Full Text] [Related]  

  • 33. A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.
    Fuchida SI; Ogura M; Ishida T; Hata H; Handa H; Katoh N; Nakaseko C; Sunami K; Katayama Y; Nobata H; Oshiro K; Iida S; Sekijima Y; Naiki H; Shimazaki C
    Int J Hematol; 2023 Oct; 118(4):443-449. PubMed ID: 37515656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis.
    Perz JB; Rahemtulla A; Giles C; Szydlo RM; Davis J; Gopaul D; Gillmore J; Mathias CJ; Hawkins PN; Apperley JF
    Bone Marrow Transplant; 2006 May; 37(10):937-43. PubMed ID: 16565738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
    Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone].
    Zhao Q; Wang L; Song P; Li F; Zhou X; Yu Y; An Z; Wang X; Zhai Y
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):283-7. PubMed ID: 27093989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
    Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression of renal amyloid deposits by VAD therapy plus autologous stem cell transplantation in a patient with primary AL amyloidosis.
    Toriu N; Sawa N; Hiramatsu R; Mizuno H; Ikuma D; Sekine A; Hayami N; Sumida K; Yamanouchi M; Hasegawa E; Hoshino J; Takaichi K; Wake A; Ohashi K; Fujii T; Ubara Y
    CEN Case Rep; 2020 Feb; 9(1):6-10. PubMed ID: 31522370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
    Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
    Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.